Almost 5% of HER2 ICD-negative breast cancer cases showed increased HER2 phosphorylation at tyrosine 877 (pHER2Y877), and trastuzumab has been shown to reduce the proliferation of HER2 ICD-negative/pHER2Y877-positive breast cancer cell lines [13]. Here, ERBB2 is linked to breast carcinoma.